Skip to main content
PLIANT THERAPEUTICS, INC. logo

PLIANT THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PLRX ISIN · US7291391057 LEI · 5493002Q5LITR7VHZH02 US Professional, scientific and technical activities
Open in API
Filings indexed 403 across all filing types
Latest filing 2026-04-22 Annual Report
Country US United States of America
Listing US PLRX

About PLIANT THERAPEUTICS, INC.

https://pliantrx.com/

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis and related diseases. The company leverages its expertise in integrin biology to create tissue-specific treatments. Its therapeutic approach centers on modulating integrin activity and inhibiting TGF-β1 signaling, which are key molecular drivers of fibrosis. Pliant utilizes its proprietary discovery platform to advance a pipeline of integrin-based product candidates, aiming to provide safer and more effective therapies for patients.

Recent filings

Filing Released Lang Actions
ARS - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
Annual Report
2026-04-22 English
DEF 14A - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
Proxy Solicitation & Information Statement
2026-04-22 English
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'Current Report' and dated March 3, 2026. It reports an amendment to the Stockholder Rights Agreement, specifically extending the expiration time of rights to March 11, 2027. The content focuses on a material definitive agreement and modification to rights of security holders. There are no financial statements or earnings data presented, nor is this an annual or quarterly report. The document is a regulatory filing reporting a material event related to shareholder rights and agreements. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 5336 characters, which is sufficient for a full 8-K report rather than a brief announcement. Therefore, the classification is RNS with high confidence.
2026-03-03 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
Major Shareholding Notification
2026-02-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.